HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Too Small A Company To Interest US Plaintiffs’ Class Action Bar? Think Again, Attorney Says

Executive Summary

Locke Lord, LLP senior counsel Sharon Blinkoff shares perspective from her experience defending smaller cosmetics companies against US class action plaintiff demands and litigation.

You may also be interested in...

Consumer Health Goliaths Face Proposed US Class Actions For ‘Natural’ ChapStick, Selsun Blue Claims

Plaintiffs take aim at Pfizer and GlaxoSmithKline in California federal court for “natural” ChapStick claims, while Sanofi US is defending the naturalness of Selsun Blue Naturals Antidandruff Shampoo in New York’s Eastern District.

Top Beauty Firms’ ‘Oil-Free’ Cosmetic Claims Targeted In US Courts

Proposed class action plaintiffs against L’Oreal USA, Johnson & Johnson Consumer and E.l.f. Cosmetics allege that “oil-free” claims are false and misleading when applied to products containing dimethicone, tocopheryl acetate, jojoba esters and/or other members of chemical functional groups constituting oil.

FTC’s Proposed Rule On ‘Made In The USA’ Claims Could Mean Increased Civil Penalties

Companies should seek legal counsel when making “Made in the USA” claims, particularly if the Federal Trade Commission’s proposed rule on the subject is adopted as drafted. Published in July, the proposed rule would enable the FTC to obtain civil penalties from violating firms “more quickly and easily," attorneys say.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts